Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp50743_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Director/PDMR Share Dealings
November 3, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that today the following Persons Discharging Managerial Responsibility (“PDMRs”) acquired American Depositary Shares (“ADSs”) in the Company under the Shire Employee Stock Purchase Plan:
|
PDMR
|
Exercise price per ADS
|
Number of ADSs
|
|
Flemming Ornskov
|
$113.94
|
109
|
|
Mark Enyedy
|
$113.94
|
109
|
|
Philip Vickers
|
$113.94
|
109
|
One ADS is equal to three Ordinary Shares of 5 pence each.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Jeff Poulton
|
jpoulton@shire.com
|
+1 781 482 0945
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX